Filed (PHiled). Greater than 1-2 years since publication

Reintervention and mortality risk after total anomalous pulmonary venous connection repair

Kevin M. Beers, Christian P. Jacobson, Stewart R. Miller, David G. Lehenbauer, Elaine Maldonado, S. Adil Husain, John H. CalhoonUniversity of Texas Health San Antonio.United States Cardiology in the YoungCardiol Young 2023; DOI: 10.1017/S1047951122004280 AbstractBackground: Management of total anomalous pulmonary venous connections has been extensively studied to further improve outcomes. Our institution previously reported factors associated with […]

Reintervention and mortality risk after total anomalous pulmonary venous connection repair Read More »

Management of Complex Pulmonary Vein Stenosis at Altitude Combining Comprehensive Percutaneous Interventional Treatment with Sirolimus, Pulmonary Hypertension Medications and Intraluminal Imaging with Optical Coherence Tomography

Michael J. Shorofsky, Gareth J. Morgan, Ernesto Mejia, Salvador A. Rodriguez, Megan Greene, Paige Sheaks, Dunbar Ivy, Jenny E. ZablahUniversity of Colorado and Children’s Hospital Colorado.United States Pediatric CardiologyPediatr Cardiol 2023; DOI: 10.1007/s00246-023-03102-3 AbstractBackground: Pulmonary vein stenosis (PVS) is a growing problem for the pediatric congenital heart population. Sirolimus has previously been shown to improve survival and

Management of Complex Pulmonary Vein Stenosis at Altitude Combining Comprehensive Percutaneous Interventional Treatment with Sirolimus, Pulmonary Hypertension Medications and Intraluminal Imaging with Optical Coherence Tomography Read More »

Novel use of riociguat in infants with severe pulmonary arterial hypertension unable to wean from inhaled nitric oxide

Liezl T. Domingo, D. Dunbar Ivy, Steven H. Abman, Alicia M. Grenolds, James T. MacLean, J. A. Breaux, Katie J. Minford, Benjamin S. FrankUniversity of Utah. University of Colorado.United States Frontiers in PediatricsFront Pediatr 2022; 10: DOI: 10.3389/fped.2022.1014922 AbstractIntroduction: Riociguat, an oral soluble guanylate cyclase stimulator, has been approved for use in adults with pulmonary arterial hypertension

Novel use of riociguat in infants with severe pulmonary arterial hypertension unable to wean from inhaled nitric oxide Read More »

Single-cell RNA sequencing and binary hierarchical clustering define lung interstitial macrophage heterogeneity in response to hypoxia

Nzali V. Campbell, Claudia Mickael, Sushil Kumar, Hui Zhang, Ian L. Campbell, Austin E. Gillen, Caio O. Trentin, Katrina Diener, Bifeng Gao, Vitaly O. Kheyfets, Sue Gu, Rahul Kumar, Tzu Phang, R. Dale Brown, Brian B. Graham, Kurt R. StenmarkUniversity of Colorado. Stanford University. University of California San Francisco.United States American Journal of Physiology Lung

Single-cell RNA sequencing and binary hierarchical clustering define lung interstitial macrophage heterogeneity in response to hypoxia Read More »

The role of macrophages in right ventricular remodeling in experimental pulmonary hypertension

Sue Gu, Claudia Mickael, Rahul Kumar, Michael H. Lee, Linda Sanders, Biruk Kassa, Julie Harral, Jason Williams, Kirk C. Hansen, Kurt R. Stenmark, Rubin M. Tuder, Brian B. GrahamUniversity of Colorado. University of California San Francisco.United States Pulmonary CirculationPulm Circ 2022; 12: DOI: 10.1002/pul2.12105 AbstractRight ventricular (RV) failure is the primary cause of death in pulmonary

The role of macrophages in right ventricular remodeling in experimental pulmonary hypertension Read More »

High-dose epoprostenol therapy in pediatric patients with pulmonary hypertension and developmental lung disease: A report of two cases

Yoshie Fukusawa, Hidenori Yamamoto, Miharu Ito, Akiko Saito, Kiyotaka Go, Yoshihito Morimoto, Kazushi Yasuda, Yoshiaki Sato, Masahiro Hayakawa, Taichi KatoNagoya University and Nagoya University Hospital. Ogaki Municipal Hospital. Japanese Red Cross Nagoya Daichi Hospital. Aichi Child Health and Medical General Center.Japan Frontiers in Pediatrics. Pediatric Cardiology SectionFront Pediatr 2023; 11: DOI: 10.3389/fped.2023.1116434 AbstractPulmonary hypertension (PH) with

High-dose epoprostenol therapy in pediatric patients with pulmonary hypertension and developmental lung disease: A report of two cases Read More »

Hemodynamically Unloading the Distal Pulmonary Circulation in Pulmonary Hypertension: A Modeling Study

Rachelle Walter, Kendall Hunter, Kurt Stenmark, Vitaly O. KheyfetsUniversity of ColoradoUnited States Journal of Biomechanical EngineeringJ Biomech Eng 2022; 144: DOI: 10.1115/1.4051719 AbstractPulmonary hypertension (PH) is a progressive disease that is characterized by a gradual increase in both resistive and reactive pulmonary arterial (PA) impedance. Previous studies in a rodent model of PH have shown that

Hemodynamically Unloading the Distal Pulmonary Circulation in Pulmonary Hypertension: A Modeling Study Read More »

Computational platform for doctor-artificial intelligence cooperation in pulmonary arterial hypertension prognostication: a pilot study

Vitaly O. Kheyfets, Andrew J. Sweatt, Mardi Gomberg-Maitland, D. Dunbar Ivy, Robin Condliffe, David G. Kiely, Allan Lawrie, Bradley A. Maron, Roham T. Zamanian, Kurt R. StenmarkUniversity of Colorado. Stanford University. George Washington University. University of Sheffield. Harvard University.United States and United Kingdom Canadian Respiratory Journal Open ResearchCRJ Open Res 2023; 9: DOI: 10.1183/23120541.00484-2022 AbstractBackground: Pulmonary arterial

Computational platform for doctor-artificial intelligence cooperation in pulmonary arterial hypertension prognostication: a pilot study Read More »

Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension

Elizabeth Colglazier, Leah Stevens, Claire Parker, Hythem M. Nawaytou, Elena K. Amin, Jasmine Becerra, Martina Steurer, Jeffrey R. FinemanUniversity of California San FranciscoUnited States Pulmonary CirculationPulm Circ 2022; 12: DOI: 10.1002/pul2.12159 AbstractDespite the increase in therapeutic options, parenteral prostacyclins remain the cornerstone in the medical management of pulmonary arterial hypertension (PAH). While the use of parenteral

Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension Read More »

Building a dedicated pediatric pulmonary hypertension program: A consensus statement from the pediatric pulmonary hypertension network

Stephanie S. Handler, Nidhy P. Varghese, Erika B. Rosenzweig, Delphine Yung, Usha Krishnan, Elise Whalen, Angela Bates, Catherine M. Avitabile, Emma O. Jackson, Russel Hirsch, Jeffrey Fineman, Steven H. Abman The Pediatric Pulmonary Hypertension Network (PPHNet)United States and Canada Pulmonary CirculationPulm Circ 2022; 12: DOI: 10.1002/pul2.12031 AbstractPediatric pulmonary hypertension (PH) is a severe, life-threatening disease associated

Building a dedicated pediatric pulmonary hypertension program: A consensus statement from the pediatric pulmonary hypertension network Read More »

Scroll to Top